Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables - Net: 2019-2024

Historic Receivables - Net for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $6.3 million.

  • Legend Biotech's Receivables - Net rose 75.32% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 75.32%. This contributed to the annual value of $6.3 million for FY2024, which is 93.72% down from last year.
  • According to the latest figures from FY2024, Legend Biotech's Receivables - Net is $6.3 million, which was down 93.72% from $100.0 million recorded in FY2023.
  • Legend Biotech's 5-year Receivables - Net high stood at $100.0 million for FY2023, and its period low was $90,000 during FY2022.
  • Over the past 3 years, Legend Biotech's median Receivables - Net value was $6.3 million (recorded in 2024), while the average stood at $35.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 99.82% in 2022, then surged by 111,056.67% in 2023.
  • Yearly analysis of 5 years shows Legend Biotech's Receivables - Net stood at $75.0 million in 2020, then crashed by 32.79% to $50.4 million in 2021, then slumped by 99.82% to $90,000 in 2022, then skyrocketed by 111,056.67% to $100.0 million in 2023, then tumbled by 93.72% to $6.3 million in 2024.